Curcumin-based Synergistic Systems for Neurokinin-3 Receptor Modulation

Publication ID: 24-11857594_0008_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Curcumin-based Synergistic Systems for Neurokinin-3 Receptor Modulation,” Published Technical Disclosure No. 24-11857594_0008_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857594_0008_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,594.

Summary of the Inventive Concept

A comprehensive system integrating curcumin compositions with distinct technologies to create a powerful platform for treating neurokinin-3 receptor-related disorders and optimizing curcumin composition efficacy.

Background and Problem Solved

The original patent identified curcumin as a potent NK3 antagonist, but its limitations included the lack of a comprehensive system for treating NK3-related disorders. The new inventive concept addresses this limitation by integrating curcumin compositions with AI, IoT, blockchain, and new materials to create a synergistic system.

Detailed Description of the Inventive Concept

The inventive concept comprises four distinct systems: a wearable device with an AI-powered analytics module for tracking neurological activity and identifying personalized treatment regimens; an IoT-enabled sensor system for monitoring physiological responses and adjusting curcumin composition formulations; a blockchain-based platform for tracking and verifying curcumin composition authenticity; and a composite material integrating curcumin with biocompatible polymers for biomedical applications. These systems work in tandem to provide a comprehensive platform for treating NK3-related disorders.

Novelty and Inventive Step

The new claims introduce novel combinations of curcumin compositions with distinct technologies, providing a synergistic system that is not obvious from the original patent. The integration of AI, IoT, blockchain, and new materials with curcumin compositions creates a new, more powerful system for treating NK3-related disorders.

Alternative Embodiments and Variations

Alternative embodiments could include integrating curcumin compositions with other distinct technologies, such as virtual reality or nanotechnology. Variations could include using different ratios of curcumin to other components or incorporating additional ingredients to enhance the system's efficacy.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the pharmaceutical and biomedical industries, particularly in the areas of neurological disorders and personalized medicine. The system's ability to provide comprehensive treatment and monitoring options could lead to improved patient outcomes and increased market share.

CPC Classifications

SectionClassGroup
A A61 A61K36/9066
A A61 A61K31/26
A A61 A61K36/82
A A61 A61P15/12

Field of Art

Pharmaceutical and biomedical technologies focused on neurokinin receptor modulation, natural compound compositions, and personalized medical treatment systems

Person of Ordinary Skill (PHOSITA) Profile

A researcher or practitioner with advanced degrees in pharmacology, biomedical engineering, or related fields, possessing expertise in receptor pharmacology, natural compound formulations, and digital health technologies

Obviousness Rationale

A PHOSITA would recognize that extending the curcumin composition's therapeutic approach through digital monitoring and personalized treatment technologies represents a predictable application of known methods in precision medicine. The source patent's focus on neurokinin-3 receptor modulation provides a clear technical foundation for exploring enhanced delivery and monitoring strategies. The proposed variations represent logical extensions of existing pharmaceutical and digital health convergence trends.

Obvious Combinations & Variations

Source Patent Element
Curcumin composition for neurokinin-3 receptor targeting
PTD Variation
IoT-enabled sensor system for monitoring physiological responses
Obviousness Reasoning
Integrating real-time physiological monitoring with drug delivery is a known technique in precision medicine, representing a predictable technological progression for optimizing therapeutic interventions
Source Patent Element
Synergistic composition ratios of curcumin and related compounds
PTD Variation
AI-powered analytics module for identifying personalized treatment regimens
Obviousness Reasoning
Developing algorithmic approaches to optimize compound ratios based on individual patient responses is a standard approach in personalized medicine research
Source Patent Element
Pharmaceutical composition with multiple natural compound components
PTD Variation
Blockchain-based platform for tracking composition authenticity
Obviousness Reasoning
Implementing supply chain verification technologies for pharmaceutical compositions is a known method for ensuring quality control and traceability
Source Patent Element
Curcumin composition with potential biomedical applications
PTD Variation
Composite material integrating curcumin with biocompatible polymers
Obviousness Reasoning
Creating advanced material formulations to enhance drug delivery and stability is a predictable approach in pharmaceutical materials engineering
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857594 and the disclosed technological variations, a person of ordinary skill in the art would find the proposed systems and methods for neurokinin-3 receptor modulation to be obvious extensions of existing pharmaceutical and digital health technologies. The combination of known techniques in personalized medicine, sensor technologies, and natural compound formulations would render the claimed innovations prima facie obvious to a skilled practitioner in the field.

Original Patent Information

Patent NumberUS 11,857,594
TitleCurcumin compositions and methods of use as an NK3 antagonist
Assignee(s)JDS Therapeutics, LLC